Faruqi & Faruqi LLP Issues Reminder to Inovio Pharmaceuticals (INO) Investors Regarding April 7, 2026 Securities Class Action Deadline

NEW YORK — A prominent national securities litigation law firm, Faruqi & Faruqi, LLP, has issued an important reminder to investors of Inovio Pharmaceuticals, Inc. regarding an ongoing federal securities class action lawsuit. Investors who purchased or otherwise acquired securities of the biotechnology company during the relevant period may be eligible to participate in the case. The firm emphasized that the deadline for investors to apply to become a lead plaintiff in the lawsuit is April 7, 2026.

The announcement serves as a critical notice to shareholders who may have suffered financial losses associated with their investments in Inovio Pharmaceuticals. The class action alleges that the company and certain executives may have violated federal securities laws by making false or misleading statements and failing to disclose key information to investors.

Background of the Investigation

Faruqi & Faruqi, LLP, a well-known national law firm focusing on securities litigation and investor rights, confirmed that it is currently investigating potential claims against Inovio Pharmaceuticals, Inc., which trades on the NASDAQ under the ticker symbol INO. The investigation follows allegations that the company may have issued misleading statements regarding aspects of its business operations, regulatory progress, or product development.

The firm has encouraged investors who experienced losses to come forward and discuss their legal options. In particular, investors who purchased or acquired Inovio securities between October 10, 2023 and December 26, 2025 may be members of the proposed class and could potentially seek compensation through the litigation process.

According to the firm, a federal securities class action lawsuit has already been filed against the company. The litigation is designed to represent investors collectively who were impacted by alleged securities law violations.

Who May Be Eligible to Participate

Individuals who invested in Inovio Pharmaceuticals within the defined class period may qualify to join the lawsuit if they incurred financial losses. The lawsuit covers those who purchased or acquired the company's securities between October 2023 and December 2025.

Key Eligibility Criteria

Investors may be eligible to participate if they meet the following conditions:

1. Purchase of Securities During the Class Period
The investor bought or otherwise acquired Inovio Pharmaceuticals securities between October 10, 2023 and December 26, 2025.

2. Financial Losses
The investor experienced measurable losses linked to their investment in the company’s stock during the relevant timeframe.

3. Ability to Demonstrate Impact
The investor can show that their losses were potentially connected to alleged misleading statements or undisclosed information provided by the company.

Eligible investors may choose to participate in the class action or seek appointment as the lead plaintiff representing other class members.

Important Deadline: April 7, 2026

The court has set April 7, 2026 as the deadline for investors wishing to serve as lead plaintiff in the case. The lead plaintiff plays a significant role in guiding the litigation process and representing the interests of other investors who are part of the class action.

While investors are not required to seek the lead plaintiff role to participate in potential compensation, the lead plaintiff typically has the largest financial interest in the case and works closely with legal counsel to direct the proceedings.

Any investor who wishes to assume this role must file a motion with the court before the deadline.

Role of the Lead Plaintiff in Securities Class Actions

In a securities class action lawsuit, the lead plaintiff acts as the primary representative of the entire group of affected investors. The responsibilities of this role include overseeing litigation decisions, communicating with attorneys, and helping shape legal strategies.

Responsibilities of the Lead Plaintiff

Directing Legal Counsel
The lead plaintiff works closely with the appointed legal team to oversee the case and ensure the interests of the class are represented.

Providing Evidence and Documentation
They may provide trading records, financial documents, and other evidence to support claims.

Representing Other Investors
The lead plaintiff acts as a representative for all class members who suffered similar financial losses.

Despite the responsibilities involved, courts typically select the investor who demonstrates the greatest financial stake and the ability to represent the class fairly.

Allegations in the Lawsuit

The complaint filed against Inovio Pharmaceuticals reportedly alleges that the company and certain executives violated federal securities laws by making misleading statements or failing to disclose material information.

Specifically, the lawsuit claims that investors may not have been fully informed about certain risks or issues related to the company’s technology, regulatory processes, or product pipeline.

According to reports, the allegations may involve statements related to the company’s proprietary medical technologies and regulatory filings associated with its therapeutic candidates.

If proven in court, such actions could constitute violations of federal securities regulations designed to protect investors and ensure transparency in financial markets.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in the United States. The company focuses on developing innovative DNA-based medicines intended to treat or prevent diseases including cancer, infectious diseases, and conditions associated with the human papillomavirus (HPV).

Inovio’s technology platform is designed to create DNA plasmids that instruct the body’s cells to produce proteins capable of triggering targeted immune responses against disease-causing pathogens or abnormal cells.

Over the years, the company has conducted numerous clinical trials and research programs aimed at advancing DNA immunotherapy technologies.

Impact on Investors and Stock Performance

The filing of securities class action lawsuits can often lead to increased scrutiny of a company’s financial disclosures and business practices. For publicly traded companies such as Inovio Pharmaceuticals, such developments may also impact investor confidence and stock price volatility.

Market analysts note that biotechnology companies can experience significant fluctuations in stock performance due to regulatory approvals, clinical trial outcomes, and investor sentiment.

When allegations of misleading statements arise, shareholders often pursue legal remedies to recover financial losses incurred as a result of inaccurate or incomplete disclosures.

Encouragement for Investors to Seek Legal Guidance

Faruqi & Faruqi partner James (Josh) Wilson, who specializes in securities litigation, is encouraging investors who suffered losses related to Inovio to contact the firm directly to discuss their rights and options.

Investors may obtain additional information about the lawsuit or discuss potential participation in the class action by reaching out to the firm through its official website or by contacting its legal team directly.

The firm also invites individuals with information regarding Inovio’s conduct — including former employees, whistleblowers, or shareholders — to share relevant details that may assist the investigation.

About Faruqi & Faruqi, LLP

Founded in 1995, Faruqi & Faruqi, LLP is recognized as a leading national securities law firm dedicated to protecting investor rights. The firm maintains offices across several major U.S. states, including New York, Pennsylvania, California, and Georgia.

Over the past several decades, the firm has recovered hundreds of millions of dollars in settlements and judgments on behalf of investors who suffered losses due to corporate misconduct and securities fraud.

The firm’s attorneys specialize in complex litigation involving securities fraud, corporate governance violations, and other financial market disputes.

Next Steps for Investors

Investors who believe they may be affected by the alleged securities law violations should consider reviewing their trading records and consulting with legal counsel to understand their rights.

Those wishing to pursue the role of lead plaintiff must submit a motion to the court before April 7, 2026. Even if investors choose not to seek this position, they may still remain members of the class and potentially benefit from any settlement or judgment that results from the case.

The investigation remains ongoing, and additional details may emerge as the litigation progresses.

Conclusion

The reminder issued by Faruqi & Faruqi underscores the importance of investor awareness and timely legal action. Shareholders who invested in Inovio Pharmaceuticals during the specified timeframe and suffered losses are encouraged to explore their legal rights and determine whether they qualify to participate in the securities class action.

With the lead plaintiff deadline approaching on April 7, 2026, investors interested in taking a more active role in the litigation should act promptly to ensure they do not miss the opportunity to seek representation in the case.

#Inovio #ClassActionLawsuit #InvestorAlert #StockMarketNews #SlimScan #GrowthStocks #CANSLIM